Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

Lutathera® demonstrated statistically significant and clinically meaningful PFS in first line advanced GEP-NETs

October 3, 2023

FAILED TRIALS: Ph 3 trials, LEAP-006 and LEAP-008, of KEYTRUDA + LENVIMA in patients with certain types of mNSCLC did not meet primary endpoints of OS & PFS

September 26, 2023

PADCEV and KEYTRUDA Significantly Improve OS and PFS in Patients With Previously Untreated Advanced Bladder Cancer in Ph 3 EV-302 Trial

September 26, 2023

Yescarta Demonstrates High Response Rate And Durable Remission In ALYCANTE Study As Initial Treatment For Transplant-Ineligible Patients With R/R LBCL

September 26, 2023

Datopotamab deruxtecan demonstrated statistically significant PFS benefit in patients with HR+ve, HER2-low/neg breast cancer in TROPION-Breast01 Ph 3 trial

September 26, 2023

Perioperative Regimen of Neoadjuvant Opdivo and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves EFS in Patients with Resectable NSCLC

September 26, 2023

Ph 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of OS and PFS in Certain Patients With 1L Locally Advanced or Metastatic Urothelial Cancer

September 26, 2023

Ph 2 EVOKE-02 Study Of Trodelvy + KEYTRUDA Demonstrates Promising Clinical Activity In 1L mNSCLC

September 19, 2023

Datopotamab deruxtecan + Imfinzi showed promising clinical activity in 1L advanced NSCLC in TROPION-Lung04 Ph 1b trial

September 19, 2023

Enhertu demonstrated strong and durable tumor responses in previously treated HER2-mutant advanced lung cancer in DESTINY-Lung02 Ph 2 trial

September 19, 2023

New Lumakras® (Sotorasib) Plus Chemotherapy Data In First-Line KRAS G12C NSCLC announced

September 19, 2023

Patritumab Deruxtecan Demonstrated Clinically Meaningful and Durable Responses in Patients with EGFR-Mutated mNSCLC in HERTHENA-Lung01 Ph 2 Trial

September 19, 2023

TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved OS in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

September 13, 2023

Ph 3 MARIPOSA-2 Study Meets Dual Primary Endpoint Resulting in PFS Improvement with RYBREVANT + Chemo +/- Lazertinib vs chemo Alone in Patients with EGFR-Mutated NSCLC after Disease Progression on Osimertinib

September 13, 2023

Positive outcome of the prespecified interim futility analysis for Ph 2b ASCEND trial of LSTA1 + SOC in patients with 1L mPDAC announced

September 13, 2023

Datopotamab deruxtecan plus Imfinzi showed promising clinical activity in the 1L advanced NSCLC setting in TROPION-Lung04 Phase Ib trial

September 13, 2023

Tagrisso plus chemotherapy extended mPFS by nearly 9 months in EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial

September 13, 2023

Phase III ALINA study of Alecensa® (alectinib), compared with platinum-based chemotherapy, met its primary endpoint of disease-free survival (DFS)

September 6, 2023

FAILED TRIAL: Ph 3 INNOVATE-3 trial of TTFields + paclitaxel in patients with platinum-resistant ovarian cancer did not meet its primary endpoint of OS

September 6, 2023

Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors Announced

September 6, 2023

Positive Results from Phase 3 CONTACT-02 Pivotal Trial of Cabozantinib + Atezolizumab in mCRPC Announced

September 6, 2023

Retevmo® (selpercatinib) Demonstrates Superior PFS Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer

September 6, 2023

Update provided on Ph 3 Skyscraper-01 study in PD-L1-high mNSCLC

September 6, 2023

FAILED TRIAL: Phase 3 LEAP-010 Trial of LENVIMA + KEYTRUDA in Patients With Certain Types of Recurrent or mSCCHN unlikely to meet primary endpoint of OS

September 6, 2023

Ph 3 Trial of TUKYSA + ado-trastuzumab emtansine Meets Primary Endpoint of PFS in Patients with Previously Treated HER2+ve Metastatic Breast Cancer

August 23, 2023
Page1 … Page16 Page17 Page18 Page19 Page20 … Page29

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.